Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

3rd International Conference on Alzheimer’s Disease & Dementia

Toronto, Canada

Guosong Liu

Guosong Liu

Neurocentria, USA

Title: Efficacy and safety of MMFS-01, a synapse density enhancer, for reversing age-related cognitive decline: a randomized, double-blind, placebo-controlled trial

Biography

Biography: Guosong Liu

Abstract

Background: Age-related cognitive decline is a major problem in elderly, affecting quality of life. Pre-clinical studies show that MMFS-01, a synapse density enhancer, is effective at reversing cognitive decline in aging rodents.rnObjective: Since brain atrophy during aging is strongly associated with both cognitive decline and sleep disorder, we evaluated the efficacy of MMFS-01 in its ability to reverse cognitive decline and improve sleep.rnMethods: We conducted a randomized, double-blind, placebo-controlled, parallel designed trial in elderly subjects (age 50-70) with complaints of memory impairment, sleep disorder, and anxiety. Subjects were treated with MMFS-01 (n=23) or placebo (n=21) for 12 weeks and cognitive ability, sleep quality, and emotion were evaluated. Overall cognitive ability was determined by a composite score of tests in four major cognitive domains.rnResults: With MMFS-01 treatment, overall cognitive ability improved significantly relative to placebo (p=0.002; Cohen\'s d=0.92). Age-related cognitive fluctuation was also reduced. Although the study population had more severe executive function deficits than age-matched controls, MMFS-01 treatment nearly restored impaired executive function, demonstrating that MMFS-01 was clinically significant. Sleep quality and anxiety were improved in MMFS-01 treatment group; however, similar degrees of improvement were also observed in the placebo control group. rnConclusions: The current study demonstrates the potential of MMFS-01 for treating age-related cognitive decline in elderly.rn